Drug Trial Radar · NCT06381570
Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas
Last checked: Nov 19, 2026Latest source record: May 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
57
Planned (sponsor's estimate)
Start
Mar 21, 2024
Primary completion
Mar 21, 2027
Study completion Mar 21, 2029
Sponsor
- Lead sponsor
- Daniel MorgensternAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The Hospital for Sick Children
- First posted
- Apr 24, 2024
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 0 weeks, up to 25 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Pilot, multicenter, open-label study of patients less than or equal to 25 years, with recurrent or progressive LGG harboring a CRAF or BRAF alteration, including BRAF V600 mutations and KIAA1549: BRAF fusions. Patients with BRAF or CRAF alterations will be identified through molecular assays as routinely performed at Clinical Laboratory Improvement Amendments (CLIA) of 1988 or other similarly certified laboratories. The study will be conducted in two sequential phases: Phase A: A Feasibility (combination dose finding) phase, followed by Phase B: An Efficacy phase. The maximum tolerated dose (MTD)/Recommended Phase 2 Dose (RP2D) of the combination as determined in Phase A would be the dose used in Phase B. The patients on Phase A who were below the MTD/RP2D would be eligible for intra-patient dose escalation to MTD/RP2D subject to criteria outlined later
Conditions
- Low-grade Glioma
Interventions
TovorafenibDrug
Tovorafenib for oral dosing is provided as an immediate-release tablet in 100 mg strength. The 100 mg tablets are red to yellowish red oval tablets. All products are labeled tovorafenib. In addition, tovorafenib is provided as a powder for reconstitution (PfR) in bottles (430mg per bottle to deliver 300 mg dose). Upon reconstitution with water, the concentration is 25 mg/mL. Vinblastine is administered by intravenous route as IV push, sites to follow local administration guidelines, once weekly (central line, but peripheral line is also permitted)
VinblastineDrug
vinblastine in combination with tovorafenib
Primary outcomes
What the sponsor says the trial is designed to measure.
- MTD/RP2DTime frame: 2 years
- Safety and TolerabilityTime frame: 2 years
- Overall response rateTime frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Hospital for Sick Children
Toronto, Ontario, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.